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ABSTRACT
canSAR (http://cansar.icr.ac.uk) is a publicly avail-
able, multidisciplinary, cancer-focused knowledge-
base developed to support cancer translational re-
search and drug discovery. canSAR integrates ge-
nomic, protein, pharmacological, drug and chemical
data with structural biology, protein networks and
druggability data. canSAR is widely used to rapidly
access information and help interpret experimental
data in a translational and drug discovery context.
Here we describe major enhancements to canSAR
including new data, improved search and browsing
capabilities, new disease and cancer cell line sum-
maries and new and enhanced batch analysis tools.
INTRODUCTION
Translating biological knowledge and discoveries from
large-scale omic data to new cancer drugs and clinical
biomarkers requires significant effort invested into under-
standing of mechanisms and experimental biological val-
idation. These experiments are greatly empowered by the
availability of as much relevant information as possible in
an easily accessible and understandable form. In our in-
creasingly multidisciplinary world, this information needs
to come from many different scientific domains that have
historically been separate.
canSAR, initially described in NAR in 2011 (1) and up-
dated in 2014 (2), is the first and, to our knowledge, re-
mains the largest multidisciplinary resource to support can-
cer drug discovery and translational research. canSAR was
developed to bring together diverse data from across all do-
mains that will benefit cancer drug discovery. It is used by
>150 000 unique users from 179 countries, and is used by
biologists, chemists and translational and clinical scientists,
from both academia and industry. Here we describe major
updates in canSAR v3.0 both in data and functionality.
DATA CONTENT AND GROWTH
canSAR’s aim is to provide comprehensive multidisci-
plinary annotation for genes and biological systems to en-
able target validation and drug discovery. canSAR con-
tains the full complement of the human proteome as well
as 528 805 proteins from 16 634 model organisms and
data for 11 778 cancer and non-transformed cell line mod-
els. Furthermore, canSAR contains 208 269 659 experi-
mental data points for 9 390 patient-derived tissue sam-
ples (for breakdown see http://cansar.icr.ac.uk/cansar/data-
sources/). There are 111 414 3D structures for 21 658 pro-
teins, collectively containing 215 178 ligands determined in
complex with a protein.We have collated 367 465 high qual-
ity experimentally derived protein–protein interactions (see
below) for 16 680 proteins which we have annotated with all
chemogenomic and structural data form canSAR.
canSAR contains chemical and pharmacological data
for over one million, bioactive, small molecule drugs and
compounds corresponding to >8 121 000 pharmacologi-
cal bioactivities as well as over 10 million calculated chemi-
cal properties. Moreover, we have now begun curating these
bioactive compounds for their suitability as investigative
chemical probes for target validation (see Target Synopsis
section below).
To our knowledge, canSAR remains the world’s most
comprehensive druggability assessment resource containing
multidisciplinary druggability assessments for the majority
of the human proteome. The latest version of canSAR pro-
vides 3D-structure-based druggability assessment for 2 836
425 cavities on 109 475 protein structures (PDB chains);
ligand-based druggability assessment for 8 197 human pro-
teins and, more recently, protein network-based druggabil-
ity results for 13 345 human proteins. Together these pro-
vide a powerful enabler for target selection and validation
for drug discovery.
The underlying architecture of canSAR is designed to
ensure full linkage of all data types across the multidisci-
plinary data contained within it. All data are linked to their
original data sources or publications, wherever available,
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Figure 1. Molecular target synopsis: new features. (A) Curated chemical probes targeting BRD4. (B) BRD4 normalised expression (z-scores) across TCGA
studies. Interactive comparison between normal (green bars) and primary tumour (blue bars) samples. Metastatic samples have been deselected in this
example. (C) NCI60 and Gene Expression Atlas cell lines ranked by BRD4 expression. (D) Mutation incidence for BRD4 across COSMIC cell lines.
Clicking on a cell line graph bar presents a detailed mutational profile for the gene. For example: (E) BRD4 mutations in colorectal cell lines.
thus ensuring data provenance and enabling researchers to
access the original studies. The data in canSAR are up-
dated at regular intervals as dictated by the data type. For
example, 3D structure data (3) and canSAR’s structure-
based druggability (4) calculations are updated weekly;
while data from the ChEMBL (5) database are typically 1–2
weeks after the ChEMBL update. Full details about the up-
dates are provided here (http://cansar.icr.ac.uk/cansar/data-
sources/).
TARGET SYNOPSIS: ENABLING BIOLOGICAL HY-
POTHESIS GENERATION
In the era of mechanism-driven drug discovery and transla-
tional research, scientists frequently need to access as much
information about a gene or target of interest in one place,
in an easily digestible form, to enable them to identify key
pieces of information and generate hypotheses for experi-
mental validation and biological exploration. The new en-
hanced canSAR Target Synopsis provides visual and tab-
ular summaries on diverse data including functional data,
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Figure 2. Disease synopsis: clinical trials. (A) Global summary of clini-
cal trials with information on approved drugs, clinical candidates, chemi-
cal probes and cell lines models applicable to each particular cancer type.
Clicking on the desired disease link, e.g. Prostate Cancer, reveals detailed
information specific to the disease (B). This includes: (i) drugs and clini-
cal candidates with chemical structure links to the detailed canSAR Com-
pound Synopsis. (ii) Timelines for applicable clinical trials, that can be fil-
tered, sorted and grouped by phase by the user. Hovering over a specific
timeline displays a brief synopsis for the trial and the bar colour reflects
protein families, 3D structure, chemical bioactivities and
pharmacological data, genetic and gene transcriptional al-
terations and pharmacologically annotated protein interac-
tion networks and other data. The Target Synopsis allows
rapid visualisation of genetic and gene transcriptional alter-
ations from patient tissue as well as cancer cell lines (Figure
1).
We also provide an individual target view on a tar-
get’s druggability using all calculable druggability assess-
ments (3D structure-based, ligand-based and network-
based druggability). canSAR contains an increasing num-
ber of manually curated drugs, clinical candidates and,
more recently, we have begun the curation of chemi-
cal probes from public repositories such as the Chemical
Probes Portal (www.chemicalprobes.org) for use in experi-
mental evaluation of the target or its pathway (Figure 1).
The immediate availability and visualisation of these data
allows researchers to rapidly gain a view about the state
of knowledge around a particular target including its alter-
ation in cancer cohorts, to assess its druggability, and to dis-
cover whether drugs or chemical tools exist to evaluate its
function.
DISEASE SYNOPSIS AND CLINICAL TRIAL DATA
A ‘disease’ view on all themultidisciplinary data in canSAR
allows rapid view and drill down into drugs approved, or
under clinical investigation, for a particular cancer type.
The ‘Disease Synopsis’ (Figure 2) provides summaries on
the number of drugs and clinical trials available for any can-
cer type or subtype and allows the exploration of key genetic
and transcriptional alterations identified in patient cohorts
as well as cancer cell line models for this cancer type. More-
over, the clinical trial view allows immediate visualisation
of the number, phases and status of drugs in clinical trials
for this cancer. We include information from>179 150 can-
cer trials. Finally, the user can also browse and explore can-
cer cell line models for a particular cancer type (Figure 2).
These data are updated monthly.
CANCER CELL LINE SYNOPSIS
Cancer cell line models remain the workhorse of cancer bi-
ological studies and target validation. Despite the plethora
of information available for cancer cell lines, few, if any, re-
sources attempted to bring all broad multidisciplinary data
together in a meaningful way. The canSAR cell-line synop-
sis summarises genetic, gene expression and pharmacolog-
ical data for 11 778 cell lines thus allowing users to iden-
tify key mutations, expressed genes and drug sensitivity be-
haviour for any given cell lines. Moreover, we have anno-
tated and clustered cell lines based on tissue and cancer
type allowing simple browsing and navigation.Most impor-
tantly, we utilize all the underlying information including
mutations, copy number alterations, gene expression and
drug sensitivity data to objectively compare all cell lines and
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
the trial phase. (iii) Cell line models relevant to the disease with sortable
links to the canSAR cell line synopsis pages.
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Figure 3. Cell line synopsis: similar cell lines. Apart from accessing the genetic, expression and pharmacological profile for a cell line of interest (e.g. PC-
3), the user can also investigate which cell lines exhibit similar features such as (A) similarity across the cell line mutational spectrum and (B) overall or
chromosome-specific copy number variation. In addition similarity can be assessed by gene expression or by drug sensitivity (not shown).
present cell line similarity rankings. This feature enables sci-
entists to select groups of cell lines with shared or comple-
mentary characteristics, based on full, objective, experimen-
tally derived data (Figure 3).
ENHANCED DRUGGABLE PROTEIN NETWORKS
One of the new unique utilities of canSAR is the automated
annotation of protein interaction networks with key phar-
macological, drug and druggability data as well as infor-
mation on alteration in cancer. This allows researchers to
view the environment around their target to explore other
proteins within its pathway or connected cellular network.
If the protein of interest is not itself druggable, or has no
chemical probes that can be used to explore the biological
activity of the pathway, then the immediate knowledge that
other proteins that interact with it are druggable or have
chemical probes becomes greatly enabling.
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Figure 4. Enhanced druggable protein networks. (A) Each interactor icon indicates the pharmacological potential and genetic information available in
canSAR. (B) Dynamically generated interactome for EGFR, using phosphorylation reactions derived from Phosphosite (purple directed interactions)
and transcriptional regulation (light blue directed interactions). Additional interaction types include Reactome Functional Interactions and molecular
complexes. The network complexity can be controlled by the number of visible nodes. The network can be saved as an image or a json object for further
analysis (e.g. in Cytoscape).
In canSAR v3.0, as well as utilizing key protein–protein
interaction databases directly (e.g. STRING (6)), we con-
structed a high confidence experimentally derived inter-
actome by combing data from the IMeX consortium (7),
Phosphosite (8) and other resources. The advantage of this
new collection of protein interaction is that it contains direc-
tional data (>5100 direct interactions are directional) and
complements the data found in other public databases.
Starting with either a single target in the Target Synopsis
or several targets using one of canSAR’s batch annotation
tools, the researcher can view and interact with protein net-
works where protein nodes are coloured by druggability and
icons indicate the availably of key information on available
drugs or chemical tools, druggability and alterations in can-
cer (Figure 4).
TOOLS EMPOWERING LARGE-SCALE BIOLOGICAL
DATA ANALYSIS
Following our successful initial implementation of the Can-
cer ProteinAnnotationTool (CPAT) and in response to user
feedback, we have enhanced CPAT and developed a new
tool, the Cancer Cell Line Annotation Tool which provides
batch-based summaries of the cell line data in canSAR.
CONCLUDING REMARKS AND FUTURE DEVELOP-
MENT
canSAR continues to grow both in content and functional-
ity to enable rapid access to data relevant to cancer trans-
lational research. canSAR provides unique views on genes
and proteins, drugs, 3D structures, protein interaction net-
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works, cancer cell lines, cancer clinical trials and more.
canSAR is globally used not only to access rapid multidis-
ciplinary knowledge, but also as the key resource to aid tar-
get selection and prioritization for drug discovery (4,9–11).
Documentation and example use cases are published on the
canSAR online documentation pages (http://cansar.icr.ac.
uk/cansar/documentation/).
canSARwill continue to expand in its data and function-
ality. We will continue the annotation of patient-derived ex-
perimental data and cancer clinical trial information and
will include clinical trial outcome data both for cancer drugs
and biomarkers. We will enhance growth and the annota-
tion of protein-network data and introduce pathways and
pathway exploration tools. Much of the focus in the next
phase of canSAR development will be on enhancing the
search and browsing power and development of expert tools
in response to user feedback.
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